Bifunctional fusion protein for novel coronavirus infection treatment and application thereof

Abstract

The invention provides a bifunctional fusion protein for resisting novel coronavirus SARS-CoV-2 and application of the bifunctional fusion protein. The bifunctional fusion protein comprises a human angiotensin converting enzyme 2, a human antibody Fc segment protein and a human tumor necrosis factor receptor 2. According to the present invention, the advantages of ACE2 and TNFR2 or GP130 are integrated, the functions of ACE2 and TNFR2 or GP130 are provided, the activity of ACE2 and TNFR2 or GP130 are not affected, the problem of antibody neutralizing ability reduction caused by virus variation can be overcome, and the risk of body injury caused by inflammatory reaction can be reduced. The bifunctional fusion protein disclosed by the invention has good neutralizing activity on a new coronavirus wild strain and a mutant strain thereof and has broad spectrum; in addition, inflammatory response can be relieved, recovery of new crown critical patients is accelerated, and compared with existing antibody drugs, the antibody has more advantages and has great clinical application prospects.

Images